#6866 FRENCH EXPERIENCE OF HOME HEMODIALYSIS PATIENTS TREATED WITH NXSTAGE HAEMODIALYSIS CYCLER WITH THE PURE FLOW SL SYSTEM

Abstract

Listen

Translate article

Abstract Background and Aims NxStage haemodialysis cycler with the Pure Flow SL system was introduced for the first time in France in June 2022. This system is designed to produce an ultrapure dialysis fluid and mixing a concentrate to the source water to prepare 60 L batch of dialysate. It can be used for a maximum of 3 home treatments. No major plumbing modifications are required to install this system at home. Here, we report to our knowledge the first French clinical evaluation of the use of the Pure Flow system in haemodialysis patients using this device and trained in NephroCare Villejuif haemodialysis center and Rouen Hospital. Method This retrospective study was performed in a cohort of 8 hemodialysis patients From June 2022 to January 2023. We describe the clinical benefits of Pure Flow including data on demographic, dialysis vintage, and short-term biological parameters. Patient related outcomes based on a specific questionary, at 3 and 6 months are also analyzed Results 8 patients were included with 5 women. The mean age was 48 years. The dialysis vintage was 24 months. The median follow-up was 4 months. 2 Patients were treated by pre-mixed 5L dialysate bags 6 months prior the implementation of Pure Flow, and 6 patients started the hemodialysis program directly with Pure Flow after a period of 10 days of training. We show that PF provide adequate dialysis dose. The mean stdkt/v was 2.3. The mean of weekly dialysate volume was 146L.We note optimal ultrafiltration rate, improvement of biological markers of adequacy. Moreover, good results technique survival was recorded. We also show Reduced handling, and setup Conclusion The NxStage with Pure Flow system is a major advantage against the premixed bags with a simple installation and a low water consumption. Its use is associated with great clinical outcomes in patients. The Pure Flow should reduce shipments and storage of dialysis treatments and facilitate the development of home hemodialysis in France. Prolonged follow-up on a cohort with a larger number of patients is necessary and will allow an appropriate evaluation of the clinical benefice of the use of the Pure Flow.